RAKOVINA THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.09 CAD | 0.00% |
|
0.00% | +5.88% |
| Apr. 09 | Rakovina Therapeutics Presents At American Association Of Cancer Research Annual Meeting | MT |
| 2023 | Rakovina Therapeutics Announces Appointment to Scientific Advisory Board | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 15.36 | 12.57 |
| Enterprise Value (EV) 1 | 12.55 | 11.67 |
| P/E ratio | -2.14 x | -4.5 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | -7.45 x | -5.51 x |
| EV / FCF | -16,885,879 x | -14,177,778 x |
| FCF Yield | -0% | -0% |
| Price to Book | 1.8 x | 2.09 x |
| Nbr of stocks (in thousands) | 69,808 | 69,830 |
| Reference price 2 | 0.2200 | 0.1800 |
| Announcement Date | 4/26/22 | 4/28/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net sales | - | - | - | - | - |
| EBITDA 1 | -0.1258 | -0.0595 | - | -2.062 | -2.281 |
| EBIT 1 | -0.126 | -0.0597 | -0.000052 | -2.474 | -2.817 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.126 | -0.0597 | -0.000052 | -5.521 | -2.791 |
| Net income 1 | -0.126 | -0.0597 | -0.000052 | -5.521 | -2.791 |
| Net margin | - | - | - | - | - |
| EPS | - | - | - | -0.1030 | -0.0400 |
| Free Cash Flow | - | - | - | -0.9095 | -0.8866 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/19/21 | 3/19/21 | 4/26/22 | 4/26/22 | 4/28/23 |
1CAD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | 0 | 2.81 | 0.9 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | -0.91 | -0.89 |
| ROE (net income / shareholders' equity) | - | - | 867% | -129% | -38.3% |
| ROA (Net income/ Total Assets) | - | -12,917% | -33% | -35.7% | -23.8% |
| Assets 1 | - | 0.000462 | 0.000158 | 15.46 | 11.71 |
| Book Value Per Share | - | - | - | 0.1200 | 0.0900 |
| Cash Flow per Share | - | - | - | 0.0400 | 0.0100 |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/19/21 | 3/19/21 | 4/26/22 | 4/26/22 | 4/28/23 |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +5.88% | 4.61M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RKV Stock
- Financials Rakovina Therapeutics Inc.
